Published 21 hours ago • loading... • Updated 8 hours ago

Indian Billionaire Dilip Shanghvi’s Sun Pharma To Buy U.S. Cancer Drug Maker For $355 Million

Sun Pharmaceutical Industries Inc. Has agreed to acquire Checkpoint Therapeutics for an upfront cash payment of $4.10 per share, totaling up to $355 million.
The acquisition includes a contingent value right for Checkpoint stockholders, potentially adding $0.70 per share based on FDA approval milestones.
The transaction aims to accelerate access to UNLOXCYT, the first FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma.
Completion of the acquisition is pending approval from Checkpoint's stockholders and other customary closing conditions.

Insights by Ground AI

Does this summary seem wrong?

55 Articles

All

Left

Center

Right

Seeking Alpha

M&A Snapshot: Sun Pharma to acquire Checkpoint Therapeutics for $355M

M&A Snapshot: Sun Pharma to acquire Nasdaq-listed Checkpoint Therapeutics for $355M

8 hours ago·United States

Read Full Article

Bloomberg

Top India Drugmaker Sun to Buy US Oncology Firm for $355 Million

Sun Pharmaceutical Industries Ltd. has agreed to buy US-based immunotherapy and oncology firm Checkpoint Therapeutics Inc. for an upfront payment of $355 million, as India’s largest drugmaker bolsters its specialty therapy portfolio.

16 hours ago·United States

Read Full Article

Buffalo News

+45 Reposted by 45 other sources

Sun Pharma to Acquire Checkpoint Therapeutics

Will add UNLOXCYT™ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for

17 hours ago·Buffalo, United States

Read Full Article

Forbes

Indian Billionaire Dilip Shanghvi’s Sun Pharma To Buy U.S. Cancer Drug Maker For $355 Million

Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and oncology company Checkpoint Therapeutics for $355 million to bolster the Mumbai-based company’s drug portfolio.

20 hours ago·United States

Read Full Article

Endpoints News

Sun Pharma to acquire Checkpoint Therapeutics and its anti-PD-L1 antibody

After months of searching for a partner for its recently approved cancer drug, Checkpoint Therapeutics has instead secured a buyer. India's Sun Pharma is acquiring the immuno-oncology biotech for $4.10 per share, or roughly ...

8 hours ago

Read Full Article

uniquetimes.org

Sun Pharma to Acquire U.S.-Based Checkpoint Therapeutics for $355 Million

Sun Pharmaceutical Industries announced on Monday its acquisition of Checkpoint Therapeutics, a U.S.-based immunotherapy and targeted oncology firm, in a $355 million deal. The transaction aligns with Sun Pharma’s strategic expansion in oncology and immunotherapy, following its recent licensing agreement with Philogen for the anti-cancer drug Fibromun. The acquisition is expected to be completed in the second quarter of 2025. The deal will bring…

9 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year